Justice Jackman has confirmed that, in the context of a preliminary discovery application, where a prospective applicant vacates a hearing date and the prospective respondent has incurred costs in preparing for the vacated hearing…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the prior three weeks ending 9 January 2026 are set out below…
Newron Pharmaceuticals and Zambon have succeeded in their preliminary discovery application against Arrotex Pharmaceuticals in the Federal Court of Australia. Newron and Zambon sought production of documents from Arrotex, for the purpose of…
Justice Rofe has handed down an interlocutory judgment dismissing Zoetis Australia Pty Ltd’s (Zoetis) application for summary dismissal of Scidera, Inc.’s (Scidera) patent infringement claims. The decision addresses a novel question of Australian patent law…
In a lengthy 1300+ paragraph judgment, Justice Downes has handed victory to Orica, finding that Orica achieved “almost complete success” in its infringement case regarding three of the four patents in suit…
Pearce IP’s CEO and Founder, Naomi Pearce, has been recognised in the IAM Strategy 300 Global Leaders 2026 – the annual showcase of the world’s leading IP strategists. This latest honour follows her previous inclusions in 2020, 2021 and 2022.
Pearce IP Patent Executive, Julie Ballance, speaks to Head of Litigation (NZ), Paul Johns, about the usefulness of Swiss-type claims in New Zealand patents, including comparisons of key points of law and practice in other countries.
No Relief for EIS – Federal Court Invalidates Pressure Wave Massager Patent and Dismisses Infringement Claims Against LELO
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 December 2025 are set out below…
Justice Burley of the Federal Court has delivered judgment in proceedings between CPC Patent Technologies Pty Ltd (CPC) and Apple Pty Limited and Apple Inc (collectively, Apple), concerning alleged patent infringement by Apple’s biometric security…
Full Court Resurrects Computer-Implemented Inventions from the Patent Graveyard. In a significant development in the long-running Aristocrat patent saga, the Full Court of the Federal Court has allowed Aristocrat Technologies Australia…
Swiss-style (or Swiss-type) patent claims have been routinely sought and granted in New Zealand for many years. However, the New Zealand courts are yet to determine the question of what conduct will infringe such a claim.
Sally Paterson and Paul Johns discuss and compare various intellectual property laws in New Zealand that provide protection for three-dimensional designs and shapes.
On 5 December 2025, Justice Burley of the Federal Court of Australia granted Janssen a preliminary injunction to restrain Juno Pharmaceuticals from launching generic versions of paliperidone palmitate long acting injectables (LAIs)…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 December 2025 are set out below…
Pearce IP’s CEO, Naomi Pearce, speaks with our Heads of Litigation for Australia and New Zealand about the practice of “skinny labelling” of generic drugs. They discuss whether a “skinny label” approach will assist in avoiding patent infringement of method of treatment or Swiss-style claims in Australia and New Zealand respectively.
Pearce IP and Leaders Recognised in Chambers Asia-Pacific 2026 Rankings for Third Consecutive Year
This article is the second in a series that explores the history of Swiss-style (Swiss-type) claims in New Zealand, the relevant law and policy considerations, and the likely judicial approach to the question of infringement.
High Court Draws Clear Line Between Trade Mark Infringement and Misleading & Deceptive Conduct in Bed Bath N’ Table Case
Swiss-style patent claims (often referred to as Swiss-type claims in New Zealand) have been routinely sought and granted in New Zealand for many years. However, the New Zealand courts are yet to determine the question of what conduct will infringe such a claim. This article is the first in a series of three that will explore the history of Swiss-style claims in New Zealand, the relevant law and policy considerations, and the likely judicial approach to the question of infringement.
The End of an Era for Pharma PTEs in AU: Full Court Excludes Formulation Patent Term Extensions in Aripiprazole (ABILIFY) Appeal
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 5 December 2025 are set out below…
This morning the Full Court published its decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161 confirming that pharmaceutical formulation patents are no longer eligible for a patent term extension in Australia.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 November 2025 are set out below…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
